Usman Baber

2009–2025 年に発表

118
論文数
19,657
被引用数
69
h 指数
117
i10 指数

被引用数

Usman Baber の年別被引用数1996 年: 被引用 1 件2003 年: 被引用 3 件2009 年: 被引用 1 件2010 年: 被引用 1 件2011 年: 被引用 6 件2012 年: 被引用 25 件2013 年: 被引用 22 件2014 年: 被引用 47 件2015 年: 被引用 45 件2016 年: 被引用 68 件2017 年: 被引用 131 件2018 年: 被引用 207 件2019 年: 被引用 678 件2020 年: 被引用 877 件2021 年: 被引用 901 件2022 年: 被引用 867 件2023 年: 被引用 683 件2024 年: 被引用 1,004 件2025 年: 被引用 594 件2026 年: 被引用 44 件1997〜2002 年は被引用が無いため表示していません2004〜2008 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,542 件、この内訳の 22%イギリス: 引用元論文 875 件、この内訳の 7.6%イタリア: 引用元論文 721 件、この内訳の 6.2%中国: 引用元論文 667 件、この内訳の 5.8%ドイツ: 引用元論文 639 件、この内訳の 5.5%オランダ: 引用元論文 480 件、この内訳の 4.2%カナダ: 引用元論文 472 件、この内訳の 4.1%フランス: 引用元論文 424 件、この内訳の 3.7%日本: 引用元論文 369 件、この内訳の 3.2%スペイン: 引用元論文 346 件、この内訳の 3%スイス: 引用元論文 335 件、この内訳の 2.9%オーストラリア: 引用元論文 322 件、この内訳の 2.8%
0%22%その他 29%

分野

  • Medicine74.7%
  • Biochemistry, Genetics and Molecular Biology13.4%
  • Immunology and Microbiology3.8%
  • Health Professions2.6%
  • Computer Science1.2%
  • Engineering1.1%
  • その他3.2%

トピック

  • Coronary Interventions and Diagnostics5.4%
  • Antiplatelet Therapy and Cardiovascular Diseases4.5%
  • Acute Myocardial Infarction Research4.1%
  • Acute Myeloid Leukemia Research3.7%
  • Cardiac Imaging and Diagnostics3.2%
  • Genetic Associations and Epidemiology3.1%
  • その他76%

共著者

全論文

検索で開く
  1. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 2,610

  2. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

    著者: , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 1,481

  3. Machine learning prediction in cardiovascular diseases: a meta-analysis

    著者: , , , , , , , , , , , , - Scientific Reports 2020 被引用: 485

  4. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting

    著者: , , , , , , , , , , , , , - Circulation 2017 被引用: 581

  5. Ticagrelor with or without Aspirin in High-Risk Patients after PCI

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gabríel Steg, Giora Weisz, Bernhard Witzenbichler, Yaling Han, Stuart Pocock, C. Michael Gibson - New England Journal of Medicine 2019 被引用: 1,000

  6. Deep learning for cardiovascular medicine: a practical primer

    著者: , , , , , , , , , - European Heart Journal 2019 被引用: 411

  7. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2025 被引用: 470

  8. Comparison of Propensity Score Methods and Covariate Adjustment

    著者: , , , , , , , , - Journal of the American College of Cardiology 2017 被引用: 716

  9. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gabríel Steg, Robert F. Storey, Jurriën M. ten Berg, Marco Valgimigli, Pascal Vranckx, Hirotoshi Watanabe, Stephan Windecker, Patrick W. Serruys, Robert W. Yeh, Marie‐Claude Morice, Dominick J. Angiolillo - Circulation 2023 被引用: 165

  10. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hani Jneid, Craig J. Beavers, Theresa M. Beckie, Jim Blankenship, Deborah B. Diercks, Bernard Lo, Clauden Louis, Faisal M. Merchant, Noreen T. Nazir, Derek So, Matthew I. Tomey, Frederick G.P. Welt - Journal of the American College of Cardiology 2025 被引用: 361

  11. Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy

    著者: , , , , , , , , , , , , , - Journal of the American College of Cardiology 2013 被引用: 278

  12. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

    著者: , , , , , , , , , , , , , , , - European Heart Journal 2019 被引用: 201

  13. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hans Lanz, Cathy Chen, Marco Valgimigli, Roland Veltkamp, Shigeru Saito, George D. Dangas - New England Journal of Medicine 2021 被引用: 264

  14. Exome-wide association study of plasma lipids in >300,000 individuals

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John C. Chambers, Daniel I. Chasman, Y Eugene Chen, Yii‐Der Ida Chen, Rajiv Chowdhury, Cramer Christensen, Audrey Y. Chu, John Connell, Francesco Cucca, L. Adrienne Cupples, Scott M. Damrauer, Gail Davies, Ian J. Deary, George Dedoussis, Joshua C. Denny, Anna F. Dominiczak, Marie‐Pierre Dubé, Tapani Ebeling, Guðný Eiríksdóttir, Tõnu Esko, Aliki‐Eleni Farmaki, Mary F. Feitosa, Maurizio Ferrario, Jean Ferrières, Ian Ford, Myriam Fornage, Paul W. Franks, Timothy M. Frayling, Ruth Frikke‐Schmidt, Lars G. Fritsche, Philippe Frossard, Valentı́n Fuster, Santhi K. Ganesh, Wei Gao, Melissa E. Garcia, Christian Gieger, Franco Giulianini, Mark O. Goodarzi, Harald Grallert, Niels Grarup, Leif Groop, Megan L. Grove, Vilmundur Guðnason, Torben Hansen, Tamara B. Harris, Caroline Hayward, Joel N. Hirschhorn, Oddgeir L. Holmen, Jennifer E. Huffman, Yong Huo, Kristian Hveem, Sehrish Jabeen, Anne Jackson, Jóhanna Jakobsdóttir, Marjo‐Riitta Järvelin, Gorm Boje Jensen, Marit E. Jørgensen, J. Wouter Jukema, Johanne Marie Justesen, Pia R. Kamstrup, Stavroula Kanoni, Fredrik Karpe, Frank Kee, Amit V. Khera, Derek Klarin, Heikki A. Koistinen, Jaspal S. Kooner, Charles Kooperberg, Kari Kuulasmaa, Johanna Kuusisto ほか 129 名 - Nature Genetics 2017 被引用: 595

  15. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - BMJ 2021 被引用: 255

  16. Prevalence, Impact, and Predictive Value of Detecting Subclinical Coronary and Carotid Atherosclerosis in Asymptomatic Adults

    著者: , , , , , , , , , , - Journal of the American College of Cardiology 2015 被引用: 452

  17. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gabríel Steg, Giora Weisz, Bernhard Witzenbichler, Yaling Han, Stuart Pocock, C. Michael Gibson, Roxana Mehran - European Heart Journal 2020 被引用: 176

  18. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott M. Damrauer, Julie A. Lynch, David E. Kaplan, Marina Serper, Philip S. Tsao, Million Veteran Program, Josep M. Mercader, Craig L. Hanis, Mark J. Daly, Joshua C. Denny, Stacey Gabriel, Sekar Kathiresan - PLoS Genetics 2020 被引用: 168

  19. Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Cardiology 2024 被引用: 86

  20. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions

    著者: , , , , , , , , , , , , , , , , - European Heart Journal 2018 被引用: 154

  21. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2016 被引用: 548

  22. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy

    著者: , , , , , , , - Journal of the American College of Cardiology 2016 被引用: 225

  23. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry

    著者: , , , , , , , , , , , , , - The Lancet 2021 被引用: 147

  24. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2024 被引用: 95